Greenwich Financial Statements From 2010 to 2022

GLSI -  USA Stock  

USD 8.50  0.55  6.92%

Greenwich Lifesciences financial statements provide useful quarterly and yearly information to potential Greenwich Lifesciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Greenwich Lifesciences financial statements helps investors assess Greenwich Lifesciences' valuation, profitability, and current liquidity needs.
We have found fourty-five available fundamental trends for Greenwich Lifesciences, which can be analyzed and compared to other ratios and to its competitors. Please verify all of Greenwich Lifesciences regular fundamental drivers against the trend between 2010 and 2022 to make sure the company can sustain itself down the road.
The current Earnings Before Interest Taxes and Depreciation Amortization EBITDA is estimated to decrease to about (4.9 M). The current Earnings before Tax is estimated to decrease to about (4.9 M).
  
Refresh
Check Greenwich Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Greenwich main balance sheet or income statement drivers, such as Operating Expenses of 4.1 M, Research and Development Expense of 3.1 M or Selling General and Administrative Expense of 992.8 K, as well as many exotic indicators such as Book Value per Share of 2.24, Current Ratio of 76.24 or Debt to Equity Ratio of 0.0151. Greenwich financial statements analysis is a perfect complement when working with Greenwich Lifesciences Valuation or Volatility modules. It can also supplement various Greenwich Lifesciences Technical models. Please check the analysis of Greenwich Lifesciences Correlation against competitors.

Greenwich Lifesciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets22.4 M27.2 M6.1 M
Increasing
Slightly volatile
Cash and Equivalents22.4 M27.2 M6.1 M
Increasing
Slightly volatile
Trade and Non Trade Payables226.7 K220.8 K6.9 M
Decreasing
Slightly volatile
Goodwill and Intangible Assets14.2 K12.6 K21.1 K
Decreasing
Slightly volatile
Total Liabilities395.3 K385.2 K7.3 M
Decreasing
Slightly volatile
Shareholders Equity29 M26.8 M(693.7 K)
Increasing
Slightly volatile
Current Assets22.4 M27.2 M6.1 M
Increasing
Slightly volatile
Assets Non Current18.5 K17.9 K22.1 K
Decreasing
Slightly volatile
Current Liabilities575 K385.2 K764.6 K
Increasing
Very volatile
Liabilities Non Current8.5 M8.6 M9.3 M
Decreasing
Slightly volatile
Total Debt317.1 K247.6 K404.3 K
Decreasing
Slightly volatile
Debt Current317.1 K247.6 K404.3 K
Decreasing
Slightly volatile
Shareholders Equity USD29 M26.8 M(693.7 K)
Increasing
Slightly volatile
Cash and Equivalents USD22.4 M27.2 M6.1 M
Increasing
Slightly volatile
Total Debt USD317.1 K247.6 K404.3 K
Decreasing
Slightly volatile

Greenwich Lifesciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General and Administrative Expense992.8 KM571.8 K
Increasing
Slightly volatile
Research and Development Expense3.1 M3.6 M1.7 M
Increasing
Slightly volatile
Operating Expenses4.1 M4.6 M2.2 M
Increasing
Slightly volatile
Weighted Average Shares10.4 M12.9 M2.8 M
Increasing
Slightly volatile
Weighted Average Shares Diluted10.4 M12.9 M2.8 M
Increasing
Slightly volatile

Greenwich Lifesciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing2.9 M2.8 M2.9 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities (282.4 K)(275.2 K)15.2 K
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares3.2 M3.1 M26 M
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(1.5 M)(1.5 M)M
Increasing
Stable
Share Based Compensation643.6 K660.6 K302.4 K
Increasing
Slightly volatile
Depreciation Amortization and AccretionK3.6 K3.6 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity(0.16)(0.16)0.4234
Decreasing
Slightly volatile
Return on Invested Capital7.818.4416.4562
Increasing
Very volatile
Price to Book Value12.1111.915.2699
Decreasing
Slightly volatile
Debt to Equity Ratio0.01510.014(0.7732)
Increasing
Slightly volatile
Current Ratio76.2470.66213.4917
Increasing
Slightly volatile
Book Value per Share2.242.073(34.0042)
Increasing
Slightly volatile
Tangible Assets Book Value per Share1.912.1020.8311
Increasing
Slightly volatile

Greenwich Lifesciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization327.5 M319.3 M420.7 M
Decreasing
Slightly volatile
Enterprise Value305.1 M290.4 M412 M
Decreasing
Slightly volatile
Average Equity30.8 M28.6 M1.2 M
Increasing
Slightly volatile
Average Assets23.7 M29.1 M5.2 M
Increasing
Slightly volatile
Tangible Asset Value22.4 M27.2 M6.1 M
Increasing
Slightly volatile
Working Capital21.7 M26.8 M5.3 M
Increasing
Slightly volatile

Greenwich Fundamental Market Drivers

Short Percent Of Float8.28%
Forward Price Earnings-11.10
Shares Short Prior Month273.89k
Average Daily Volume Last 10 Day155.32k
Average Daily Volume In Three Month74.02k
Date Short Interest13th of May 2022
Fifty Day Average15.06
Two Hundred Day Average26.89

About Greenwich Lifesciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Greenwich Lifesciences income statement, its balance sheet, and the statement of cash flows. Greenwich Lifesciences investors use historical funamental indicators, such as Greenwich Lifesciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences investors may use each financial statement separately, they are all related. The changes in Greenwich Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Greenwich Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Greenwich Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Greenwich Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Greenwich Lifesciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Greenwich Lifesciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of Greenwich Lifesciences Correlation against competitors. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.